Brexit

Brexit

Brexit—key steps, concepts and timeline

By way of background, Practice Note: Brexit—exiting the EU under Article 50 [Archived] explains the operation of the withdrawal process under Article 50 of the Treaty on European Union and considers some of the key issues and the consequences arising in the context of the UK becoming the first EU Member State to withdraw its membership.

Our Brexit legislation tracker records the progress of UK legislation introduced as part of the legislative project associated with the UK’s withdrawal from the EU. Also see: Brexit legislation tracker 2017–19 [Archived], which tracked the progress of primary legislation introduced as part of the legislative preparation for the UK’s withdrawal from the EU during the 2017–19 Parliament.

From the point of its exit from the EU (31 January 2020), the UK’s relationship with the EU was governed by the Withdrawal Agreement, an international treaty negotiated by the UK and the EU during the withdrawal period, which was introduced to:

•
tie up the administrative and financial loose ends associated with the UK’s membership of the EU
•
protect the rights of UK and EU citizens living in each

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

MHRA reports clinical trial approval times halved following regulatory reforms

The Medicines and Healthcare products Regulatory Agency (MHRA) has reported that clinical trial approval times have been reduced from an average of 91 days to 41 days following the implementation of risk-proportionate regulatory reforms and digital platforms introduced in 2023. Research published in the British Journal of Clinical Pharmacology on 6 October 2025 analysed over 4,600 clinical trial applications, finding that 99% of initial applications were completed within the statutory 30-day timeframe. The reforms include a fast-track route enabling lower-risk studies to be approved within 14 days and the deployment of artificial intelligence tools to support regulatory assessments. New legislation taking effect in April 2026 will require all UK clinical trials to publicly register and publish their results, including plain-language summaries for participants. The legislation will also extend the deadline for sponsors to respond to regulator feedback from 14 to 60 days, intended to align with international trial timelines. The MHRA's Combined Review process with the Health Research Authority now runs ethical and regulatory assessments in parallel to reduce duplication for researchers.

MHRA updates clinical investigations guidance for medical device

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its guidance on clinical investigations for medical devices, with revisions published on 6 October 2025. The updates incorporate new flow charts and accompanying guidance (August 2025) clarifying when notification to MHRA is required under the UK Medical Devices Regulations 2002.

EMA launches AI research priorities survey to inform regulatory focus

The European Medicines Agency (EMA) has launched an EU survey ran by the joint HMA-EMA Network Data Steering Group (NDSG) to identify key research priorities for artificial intelligence (AI) in the development and evaluation of medicines. It aims to gather structured input from stakeholders including the European Medicines Regulatory Network (EMRN), industry, SMEs, patients, consumers, academics and healthcare professionals. Survey feedback will be used to define priority areas that can support safe and effective use of AI in medicine, with the findings to be shared with the broader research community to advance academic and multi-stakeholder research. The survey forms part of the NDSG’s 2025–2028 workplan to optimise data use and leverage AI for better decision-making in medicines regulation. The survey closes on 17 October 2024.

EMA publishes EU network data strategy following public consultation

The European Medicines Agency (EMA) has published the European Medicines Agencies Network Data Strategy on 3 October 2025, following a public consultation conducted between November and December 2024. The strategy focuses on making more effective use of data hosted by the European medicines regulatory network and aims to ensure data meets high quality standards whilst being appropriately organised, standardised and easily shared among regulators and stakeholders. The document, reference number EMA/128369/2025, is intended to facilitate collaboration and more informed regulatory decision-making across the network. The strategy builds on EMA's existing work in leveraging data including regulatory submissions data, substance and product master data, and real-world data such as electronic health records and patient registry data to support public health decisions in the European Union.